Home				Orphan Diseases Drug Development Weekly - Y2007 week 02
DATE	SOURCE	OTHER PARTY INVOLVED	INDICATION(S)	HEADLINES - CLICK TO VIEW FULL RELEASE
01/12/07	Point Therapeutics (US)		Pancreatic cancer (metastatic)	Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
01/11/07	AnGes MG (JP)	Vical (US)	Melanoma (metastatic)	AnGes MG, Vical to Start Phase III Clinical Trial of Allovectin for Gene Therapy
01/11/07	Chelsea Therapeutics International (US)	Dainippon Sumitomo Pharma (JP)	Neurogenic orthostatic hypotension	Chelsea Therapeutics Announces Results of European Phase IIb Trial of Droxidopa
01/10/07	Viralytics (US)		Melanoma (metastatic)	Ethics Committee Approval to conduct a Phase I study in Breast, Prostate and Melanoma Cancer patients using CAVATAKTM administered intravenously
01/09/07	Anthera Pharmaceuticals (US)		Acute chest syndrome	Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell…
01/09/07	Biogen Idec (US)		Multiple sclerosis	Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis
01/09/07	Genzyme (US)		Various	Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude Productive Year
01/09/07	Medarex (US)	BioWa (US)	Hodgkin's disease (relapsed or refractory)	BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced…
01/08/07	Allos Therapeutics (US)		Lymphoma (peripheral T-cell)	Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell…
01/08/07	Human Genome Sciences (US)		Various	Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare…
01/08/07	Osiris Therapeutics (US)		Crohn disease	Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn’s Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial